NEW YORK (GenomeWeb) – Investment bank Mizuho Securities has upgraded shares of Fluidigm from Neutral to Buy citing improved end markets and the expected effects from the firm's recent acquisition of DVS Sciences.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The US is heading toward another budget showdown, Nature News says.